FDA advisory panel: asthma drugs should stay on market

Share this article:
An FDA advisory panel Wednesday voted unanimously in favor of continued marketing by GlaxoSmithKline and Novartis of three long-acting beta-agonist bronchodilators.
The panel also ruled that a boxed warning should be added to Novartis' Foradil (formoterol) explaining that increases in asthma-related deaths have been seen in studies of the agent salmeterol, which is contained in GSK's Serevent and Advair. The two GSK drugs have carried the warning since 2003.
Although salmeterol and formoterol have not been directly compared, Foradil appears to work differently, Novartis said in FDA briefing materials. Nevertheless, "If FDA decides to adopt the recommendation of the committee, we will work closely with the agency to finalize the appropriate language," Novartis and Schering-Plough said in a joint statement. Foradil is marketed by Schering-Plough in the U.S.
The meeting of FDA's Pulmonary-Allergy Drugs Advisory Committee came amid serious safety concerns raised by postmarketing studies of the drugs. A GSK trial known as SMART, announced in 2003, found 13 deaths among about 13,000 patients treated for 28 weeks with Serevent, compared with three deaths among about 13,000 placebo takers.
Severe asthma attacks also were reported in patients taking Foradil at doses above the FDA-approved dose. Another study done after approval was too small to draw conclusions from, the panel said.
The panel also looked at adverse event reports recorded in the FDA Adverse Events Reporting System database and reported among users of all three products, up to the last quarter of 2004.
Advair is a combination of Serevent and the agent fluticasone propionate. U.S. sales totaled $2.9 billion in 2004, according to IMS. Serevent registered U.S. sales of $273 million that year.
Foradil had U.S. sales of $82 million in 2004.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...